JP2016525093A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525093A5 JP2016525093A5 JP2016524633A JP2016524633A JP2016525093A5 JP 2016525093 A5 JP2016525093 A5 JP 2016525093A5 JP 2016524633 A JP2016524633 A JP 2016524633A JP 2016524633 A JP2016524633 A JP 2016524633A JP 2016525093 A5 JP2016525093 A5 JP 2016525093A5
- Authority
- JP
- Japan
- Prior art keywords
- nhc
- phenyl
- alkyl
- nhso
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013902513 | 2013-07-08 | ||
| AU2013902513A AU2013902513A0 (en) | 2013-07-08 | Method of treatment or prophylaxis | |
| PCT/AU2014/050116 WO2015003223A1 (en) | 2013-07-08 | 2014-07-08 | Heterocyclic compounds and methods of their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016525093A JP2016525093A (ja) | 2016-08-22 |
| JP2016525093A5 true JP2016525093A5 (enExample) | 2017-08-17 |
| JP6505682B2 JP6505682B2 (ja) | 2019-04-24 |
Family
ID=52279233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524633A Expired - Fee Related JP6505682B2 (ja) | 2013-07-08 | 2014-07-08 | ヘテロ環式化合物およびそれらの使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9714224B2 (enExample) |
| EP (1) | EP3019477B1 (enExample) |
| JP (1) | JP6505682B2 (enExample) |
| CN (1) | CN105358532B (enExample) |
| ES (1) | ES2883155T3 (enExample) |
| NZ (1) | NZ630908A (enExample) |
| PL (1) | PL3019477T3 (enExample) |
| PT (1) | PT3019477T (enExample) |
| WO (1) | WO2015003223A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6232384B2 (ja) | 2012-01-06 | 2017-11-15 | ノバルティス アーゲー | 複素環式化合物およびその使用方法 |
| ES2898635T3 (es) * | 2015-03-12 | 2022-03-08 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| CN106478502B (zh) * | 2015-08-29 | 2021-04-27 | 上海翰森生物医药科技有限公司 | 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用 |
| KR102132761B1 (ko) * | 2017-06-09 | 2020-07-17 | 산동 단홍 파머수티컬 컴퍼니., 리미티드. | At2r 수용체 길항제로서의 카르복시산 유도체 |
| US11485725B2 (en) | 2017-12-15 | 2022-11-01 | Auransa Inc. | Derivatives of piperlongumine and uses thereof |
| US11384097B2 (en) | 2018-06-19 | 2022-07-12 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Tetrahydroisoquinoline derivative, preparation method therefor and use thereof |
| WO2020012266A1 (en) * | 2018-07-12 | 2020-01-16 | Novartis Ag | Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase |
| WO2020228436A1 (zh) | 2019-05-10 | 2020-11-19 | 浙江海正药业股份有限公司 | 芳环或杂芳环类衍生物及其制备方法和用途 |
| CN111620816B (zh) * | 2020-05-27 | 2023-06-02 | 上海赛默罗生物科技有限公司 | 螺桨烷类衍生物、其制备方法、药物组合物和用途 |
| CN113880825B (zh) * | 2020-07-01 | 2025-03-14 | 浙江海正药业股份有限公司 | 四氢异喹啉类衍生物的盐、其制备方法及其医药应用 |
| CN111777555B (zh) * | 2020-09-04 | 2020-12-01 | 上海赛默罗生物科技有限公司 | 脂肪环烷衍生物、其制备方法、药物组合物和其应用 |
| AU2022318349B2 (en) | 2021-07-30 | 2025-12-18 | Confo Therapeutics N.V. | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling |
| CN117603088A (zh) * | 2023-10-28 | 2024-02-27 | 广东工业大学 | 一种基于氨基酸乙酯的芳香醛席夫碱及其在不对称烷基化中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55127373A (en) * | 1979-03-26 | 1980-10-02 | Takeda Chem Ind Ltd | Tetrahydroisoquinoline compound and its preparation |
| US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5236934A (en) * | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| US6649606B1 (en) * | 2001-11-09 | 2003-11-18 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| WO2006055951A2 (en) * | 2004-11-19 | 2006-05-26 | Portola Pharmaceuticals, Inc. | Tetrahydroisoquinolines as factor xa inhibitors |
| NZ555334A (en) | 2004-12-24 | 2010-05-28 | Spinifex Pharm Pty Ltd | Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist |
| JP5230595B2 (ja) | 2006-03-20 | 2013-07-10 | スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド | 炎症性疼痛の治療または予防の方法 |
| ES2560327T3 (es) * | 2010-01-19 | 2016-02-18 | Novartis Ag | Métodos y composiciones para una velocidad de conducción nerviosa mejorada |
| NZ605444A (en) | 2010-07-21 | 2015-06-26 | Spinifex Pharm Pty Ltd | Salt and solvates of a tetrahydroisoquinoline derivative |
| JP6232384B2 (ja) | 2012-01-06 | 2017-11-15 | ノバルティス アーゲー | 複素環式化合物およびその使用方法 |
| JP6258867B2 (ja) | 2012-01-25 | 2018-01-10 | ノバルティス アーゲー | 複素環式化合物およびその使用方法 |
| EP2807171B1 (en) | 2012-01-25 | 2020-08-12 | Novartis AG | Heterocyclic compounds and methods for their use |
-
2014
- 2014-07-08 NZ NZ630908A patent/NZ630908A/en unknown
- 2014-07-08 CN CN201480038866.XA patent/CN105358532B/zh not_active Expired - Fee Related
- 2014-07-08 EP EP14823688.8A patent/EP3019477B1/en active Active
- 2014-07-08 PL PL14823688T patent/PL3019477T3/pl unknown
- 2014-07-08 ES ES14823688T patent/ES2883155T3/es active Active
- 2014-07-08 WO PCT/AU2014/050116 patent/WO2015003223A1/en not_active Ceased
- 2014-07-08 PT PT148236888T patent/PT3019477T/pt unknown
- 2014-07-08 US US14/903,166 patent/US9714224B2/en active Active
- 2014-07-08 JP JP2016524633A patent/JP6505682B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017511815A5 (enExample) | ||
| JP2017524025A5 (enExample) | ||
| JP2014504622A5 (enExample) | ||
| JP2019518766A5 (enExample) | ||
| ZA201507958B (en) | New somatostatin receptor subtype 4 (sstr4)agonists | |
| JP2016531126A5 (enExample) | ||
| JP2013502430A5 (enExample) | ||
| JP2013502431A5 (enExample) | ||
| JP2015506348A5 (enExample) | ||
| JP2016514697A5 (enExample) | ||
| JP2015504067A5 (enExample) | ||
| JP2015500843A5 (enExample) | ||
| JP2015509098A5 (enExample) | ||
| JP2017523169A5 (enExample) | ||
| JP2013508288A5 (enExample) | ||
| JP2012521411A5 (enExample) | ||
| JP2018504441A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| EA201391558A1 (ru) | Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения | |
| JP2018531954A5 (enExample) | ||
| JP2018521056A5 (enExample) | ||
| JP2017534665A5 (enExample) | ||
| JP2019510086A5 (enExample) | ||
| WO2012122028A3 (en) | Pyrazinoisoquinoline compounds | |
| JP2017526701A5 (enExample) |